What’s more, addition of a multitargeted receptor tyrosine kinase inhibitor sunitinib also amplified the anti-tumor effects of JX-594, by improving anti-tumor immune responses such as increasing CD8+ T-cell recruitment and decreasing Tregs and MDSCs (118). Here, CD8A is linked to neoplasm.